Cassava Sciences, Inc. (SAVA)
| Market Cap | 1.69B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.23M |
| Shares Out | 24.97M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | 34.01 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $43.41 |
| Previous Close | $44.48 |
| Change ($) | -1.07 |
| Change (%) | -2.41% |
| Day's Open | 45.26 |
| Day's Range | 35.62 - 45.46 |
| Day's Volume | 4,066,974 |
| 52-Week Range | 1.63 - 117.54 |
Its promising potential treatment for Alzheimer's disease is going to enter phase 3 trials later this year.
SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer's disease study. The post Why Cassava Sciences Has Tremendous Upside Potential appeare...
Cassava Sciences will likely be a winner in the fight against Alzheimer's. If successful, SAVA stock is worth significantly more.
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been i...
Cassava Sciences Inc (NASDAQ: SAVA) completes an End-of-Phase 2 (EOP2) meeting with the FDA for its lead candidate, simufilam, in Alzheimer's disease. The FDA and Cassava Sciences agree on key...
- Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New Drug Application Filing for Simufilam in Alzheimer's disease -
Is (SAVA) Outperforming Other Medical Stocks This Year?
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $51.22, moving -1.18% from the previous trading session.
These momentum stocks have been printing money for retail investors in recent weeks.
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...
This company's experimental Alzheimer's disease drug looks very promising, but there are a few key caveats.
Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at $49 per share, for gross proce...
AUSTIN, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...
Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.
Can this company's Alzheimer's disease candidate deliver further gains ahead?
Find out what these two red-hot stocks are doing to earn investors' love.
Cassava Sciences Inc (NASDAQ: SAVA) shares were trading solidly higher Monday on above-average volume in reaction to updates from the company on clinical programs and upcoming catalysts. The A...
AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today anno...
Of the stocks with volatile price action this week, perhaps the wildest has been Cassava Science Inc. (NASDAQ: SAVA) — the PreMarket Prep Stock of the Day. The Company: Cassava Sciences Inc is...
Cassava Sciences said Thursday its Alzheimer's treatment showed promise in a six-month study and SAVA stock bolted to a record high. The study is still enrolling patients.
Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.
Cassava Sciences Inc (NASDAQ: SAVA) shares rallied over 97% today in the regular and after-hours sessions. What Happened: The upwards movement was an extension from a day ago when shares rose ...
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Cassava Sciences (SAVA) stock is on the rise Wednesday after revealing interim results from a recent Alzheimer's disease clinical trial. The post SAVA Stock: 12 Things for Investors to Know Ab...
Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.
The biotech's experimental Alzheimer's treatment could be a game changer.
Cassava Sciences (NASDAQ: SAVA) shares are trading higher Tuesday after the company announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for ...
Shares of Cassava Sciences soared as much as 221% Tuesday after the biopharmaceutical company announced upbeat data on its leading drug candidate for the treatment of Alzheimer's disease. The ...
Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat ...
Interim analysis of the first 50 patients to complete 6 months of sumifilam treatment came sooner than we expected. The results are nothing short of phenomenal and historic - "Patients' cognit...
It's been 20 days since we released a report on Cassava Sciences saying it could be the best-performing stock of 2021. The stock has already doubled, but we think this is just the beginning.
These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease. Dr. Kupie...
As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).
Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...
A public offering is weighing on the biophama's shares today.
AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...
This biotech titan should be a top player on the merger and acquisition scene next year.
AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today reported financial results ...
Cassava Sciences (SAVA) is in the news Wednesday after announcing data from a recent clinical trial concerning Alzheimer's disease. The post Cassava Sciences News: Why SAVA Stock Is Soaring 24...
Alzheimer's Patients Treated with Sumifilam Show ed a Statistically Significant (p
Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.
A positive note from an investment bank about the biotech caught investors' attention.
About SAVA
Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
| Industry Biotechnology | Founded 1998 |
| CEO Remi Barbier | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol SAVA |
Analyst Forecasts
According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 67.00, which is an increase of 54.34% from the latest price.